Exelixis, Inc. (NASDAQ:EXEL) announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society …
On August 19th, Exelixis, Inc. (NASDAQ:EXEL) entered into additional, privately negotiated exchange agreements with certain holders of the company’s 4.
Leerink praises significant upside opportunities for Exelixis’ pipeline
Ever since Exelixis, Inc. (NASDAQ:EXEL) gained approval from the FDA allowing its pipeline drug to be released for treatment of second-line advanced renal …
Piper Jaffray analyst, Edward Tenthoff, reiterates his Neutral rating on Elelixis, Inc. (NASDAQ:EXEL) following the company’s quarterly results.
Exelixis, Inc. (NASDAQ:EXEL) is set to release its second-quarter financial results after the markets close on Wednesday, August 3rd.
Leerink Swann analyst Michael Schmidt was out pounding the table on Exelixis, Inc. (NASDAQ:EXEL) Tuesday, reiterating an Outperform rating and price target of $10, which represents a potential upside …
With more than 30,000 attendees, the American Society of Clinical Oncology (ASCO) annual meeting is the largest cancer conference in the world. As …
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is plummeting nearly 50% down to $4.55 after the FDA rejected the company’s New Drug Application for the second …
There’s good news all around as Exelixis, Inc. (NASDAQ:EXEL) releases promising data in an attempt to expand the indication of one of its …
